Castlight Health CSLT 深 沪
等待开盘 10-29 09:30:00 美东时间
2.05
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 2.05
- 总市值 3.35亿
- 52周最高 2.71
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.35
- 委 比 0.00%
- 总股本 1.64亿
- 历史最高 41.95
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.60
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Castellum, Inc. to Attend the 2025 Maxim Growth Summit
Castellum, Inc. (NYSE-American: CTM) will participate in the 2025 Maxim Growth Summit from October 22-23 at The Hard Rock Hotel NYC. The event features industry leaders, including Larry Kudlow and Christopher Ruddy, and covers sectors like biotechnology, AI, and energy. Castellum focuses on cybersecurity and software engineering for the federal government. www.maximgrp.com/2025-growth-summit.
10-20 10:45
Castellum, Inc.’s Subsidiary Specialty Systems, Inc. Adds IT Services for GSA MAS Contract
Castellum, Inc.'s subsidiary, Specialty Systems, Inc. (SSI), has added Special Item Number (SIN) 54151S to a new General Services Administration (GSA) Multiple Award Schedule (MAS) contract, enabling SSI to bid on competitive contracts related to information technology professional services. This addition also allows SSI to leverage its joint venture with protégé Epic Systems, Inc., as both now have contracts on the 54151S SIN. SSI can now respon...
10-14 10:45
Castellum, Inc. Announces Aggregate Warrant Exercises Raising Additional Proceeds of Approximately $4.5 Million
Castellum, Inc. announced that investors have exercised 3,673,666 stock warrants, raising approximately $4.5 million in gross proceeds. This follows the company’s June 12, 2025 public offering of 4,166,667 units. The company plans to use the funds to invest in growth initiatives, with CEO Glen Ives expressing confidence in ending 2025 with strong momentum. Castellum provides cybersecurity, electronic warfare, and software engineering services to ...
08-14 10:45
Castellum, Inc. Teams with Quarrio to Provide Trustworthy Agentic AI for Government
Castellum, Inc. has entered a reseller agreement with Quarrio Corporation to provide trustworthy AI solutions for the U.S. Government. The partnership focuses on enhancing decision-making through accurate, consistent, and secure AI technology, aligning with Castellum's cybersecurity and software services. Both CEOs expressed confidence in the collaboration's potential to improve government operations by leveraging advanced AI capabilities.
08-12 10:45
Castellum, Inc. Reports Record Quarterly Revenue, Improving Profitability, and Additional Debt Reduction with Q2 2025 Results
Castellum, Inc. reported record second-quarter 2025 revenue of $14.0 million, up 19.7% from Q1 2025 and 21.7% from Q2 2024. The company reduced debt by $3.7 million, narrowed operating loss to $(0.4) million, and ended with a record cash balance of $14.7 million. Adjusted EBITDA was $0.5 million. CEO Glen Ives highlighted strong performance and progress driven by the company's skilled team, positioning it well to create long-term shareholder valu...
08-08 10:45
Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference
Castle Biosciences announced that its executive management will present a company overview at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025, at 12:30 p.m. Eastern time. A live audio webcast will be available on the company’s website, with a replay following the event. The company, focused on improving health through innovative diagnostic tests for diseases like skin cancer and uveal melanoma, also highlighted its R&D init...
07-29 11:00
Castle Biosciences’ Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal
Derek Maetzold, founder, president, and CEO of Castle Biosciences, was named a 2025 Most Admired CEO by the Houston Business Journal. The award recognizes leaders who demonstrate outstanding financial stewardship, foster inclusive workplace cultures, and contribute to the Houston community. Maetzold has led Castle Biosciences to improve patient outcomes through innovative diagnostic tests for skin cancers, Barrett's esophagus, and uveal melanoma....
07-25 11:00
Castellum, Inc. Publishes Letter to Shareholders
Castellum, Inc. CEO Glen Ives released a letter to shareholders, highlighting the company's progress over the past year. Since assuming the CEO role in July 2024, Castellum has transitioned to Phase 2, focusing on organic growth and strengthening its foundational platform. Key achievements include raising over $16 million, reducing long-term debt to under $5 million, winning a $103.3 million contract, establishing mentor-protégé relationships, an...
07-14 10:45
Evolent announces key appointments to leadership team
Dr. David Lim joins Evolent as chief clinical officer John Way joins Evolent as CFO, Performance Suite WASHINGTON, July 9, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company fo...
07-09 20:00
Castellum, Inc. Announces Creation of New Subsidiary to Focus on Advanced Technology Products
Castellum, Inc., a cybersecurity and software services company, announced the creation of a new wholly owned subsidiary, Castellum Advanced Technology Products, Inc. (CATP), to focus on developing advanced technology products and potential equity investments in tech companies. CEO Glen Ives emphasized that leveraging cutting-edge technology is crucial for modern defense strategies. The move aims to enhance Castellum's ability to deliver better so...
06-24 10:45
